Single-dose pharmacokinetics and cardiovascular effects of oral pimobendan in healthy cats.

摘要: Abstract Introduction To investigate the pharmacokinetics and pharmacodynamics of oral pimobendan in conscious, healthy cats. Animals Eight adult Materials methods A randomised, single-blinded, crossover design was used. Two doses (0.625-mg [LD], 1.25-mg [HD]) a control substance (3-mL water) were administered to each cat. Blood collection, echocardiography, oscillometric blood pressure measurements performed repeatedly for 12 h following dose. Plasma concentrations active metabolite, O-desmethylpimobendan (ODMP), quantified using ultra-high-performance liquid chromatography tandem mass spectrometry. Cardiovascular parameters evaluated between- within-treatment effects over time linear mixed modelling. Results Pimobendan rapidly absorbed converted ODMP with AUC0–∞ greater than (ODMP:pimobendan ratio 0.6 [LD] 0.5 despite longer elimination half-life (pimobendan t1/2 0.8 h vs. 1.6 h [LD]; 0.7 h 1.3 h [HD]). Averaged across all points, increased several measures systolic function; however, its effect could not be further characterised. Although treatment well-tolerated, two cats vomited HD another had ventricular premature beat recorded LD. Conclusions The lower ODMP:pimobendan compared that observed previously dogs suggests reduced metabolism Treatment duration action differences between Further studies are required evaluate feline cardiovascular medicine.